OTC Markets OTCPK - Delayed Quote USD

Galderma Group AG (GDERF)

226.67 +0.67 (+0.30%)

At close: October 30 at 4:00:00 PM EDT

What Makes Galderma Group AG - Unsponsored ADR (GALDY) a New Strong Buy Stock

Zacks 5mo ago

GALD.SW

GALDY

GDERF
+0.30%
Galderma (SWX:GALD) Stock Could Be 39% Undervalued Following China Approval

Simply Wall St. 8d ago

GALD.SW

GALD
Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines

Business Wire 9d ago

GALD.SW
Galderma raises 2026 sales growth outlook after Q3 revenue beats forecasts

Investing.com 10d ago

GALD.SW
Galderma Delivers Net Sales of 4.765 B USD in the First Nine Months, Up 25.1% at Constant Currency Year-on-Year, and Raises Full-Year Net Sales Guidance

Business Wire 10d ago

GALD.SW
AMWC Dubai 2026: Galderma Reinforces Its Injectable Aesthetics Leadership

Business Wire 11d ago

GALD.SW
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis

Business Wire 17d ago

GALD.SW
Galderma Signs Agreement to Acquire ZO Skin Health, Strengthening Its Physician-Dispensed Skincare Offering

Business Wire 18d ago

GALD.SW
Galderma to buy Blackstone-owned ZO Skin Health for $1.5 bln

Investing.com 18d ago

OR.PA

GALD.SW
New Galderma Research Reveals More Than Half of Women Mistake Menopause-Related Skin Changes for Signs of Ageing

Business Wire 19d ago

GALD.SW
Fall Clinical 2026: Galderma Presents New Three-Year Nemluvio® Data Showing Deep and Lasting Skin Lesion and Itch Responses in Patients With Atopic Dermatitis Aged 12 and Older

Business Wire 24d ago

GALD.SW
30 Years of Restylane®: Reshaping the Aesthetics Field Through Science-Led, Patient-Centric Innovation

Business Wire 26d ago

GALD.SW

U.S. markets closed

Galderma Group AG (GDERF)

What Makes Galderma Group AG - Unsponsored ADR (GALDY) a New Strong Buy Stock

Galderma (SWX:GALD) Stock Could Be 39% Undervalued Following China Approval

Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines

Galderma raises 2026 sales growth outlook after Q3 revenue beats forecasts

Galderma Delivers Net Sales of 4.765 B USD in the First Nine Months, Up 25.1% at Constant Currency Year-on-Year, and Raises Full-Year Net Sales Guidance

AMWC Dubai 2026: Galderma Reinforces Its Injectable Aesthetics Leadership

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis

Galderma Signs Agreement to Acquire ZO Skin Health, Strengthening Its Physician-Dispensed Skincare Offering

Galderma to buy Blackstone-owned ZO Skin Health for $1.5 bln

New Galderma Research Reveals More Than Half of Women Mistake Menopause-Related Skin Changes for Signs of Ageing

Fall Clinical 2026: Galderma Presents New Three-Year Nemluvio® Data Showing Deep and Lasting Skin Lesion and Itch Responses in Patients With Atopic Dermatitis Aged 12 and Older

30 Years of Restylane®: Reshaping the Aesthetics Field Through Science-Led, Patient-Centric Innovation